Previous close | 0.00 |
Open | 17.53 |
Bid | 15.68 x 47300 |
Ask | 18.04 x 34100 |
Day's range | 17.53 - 17.53 |
52-week range | 12.48 - 19.84 |
Volume | |
Avg. volume | 1,895 |
Market cap | 26.488B |
Beta (5Y monthly) | 0.47 |
PE ratio (TTM) | 38.78 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.17 (0.93%) |
Ex-dividend date | 27 Sept 2024 |
1y target est | N/A |
Terumo's (TRUMY) subsidiary MicroVention's WEB 17 device, used in treating intracranial aneurysms, demonstrates high safety and effectiveness in the CLEVER study.
Terumo (TRUMY) subsidiary Microvention's SOFAST study validates the SOFIA Flow Plus Aspiration Catheter's speed, efficacy and safety in stroke thrombectomy.
Terumo (TRUMY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.